CATHERINE HARTJOY: Open Payments
NPI 1275520066 · TACOMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,101 in 46 payments from 20 companies in 2025. Trend: 2023 $808 · 2024 $986 · 2025 $1,101
Food & beverage: $1,101
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $222 |
| AstraZeneca Pharmaceuticals LP | 8 | $185 |
| Lilly USA, LLC | 4 | $163 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| GlaxoSmithKline, LLC. | 2 | $48 |
| Novo Nordisk Inc | 2 | $46 |
| Amgen Inc. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $34 |
| Antares Pharma, Inc. | 1 | $31 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $31 |
Products named: JARDIANCE, UBRELVY, AIRSUPRA, FARXIGA, QULIPTA, REXULTI, VRAYLAR, TRELEGY ELLIPTA.
Industry payments across WA — which companies pay providers there.
